DASH
Repository logo
Communities & Collections
Browse DASH
DASH Stories
Statistics
  1. Home
  2. Faculty of Arts and Sciences
  3. FAS Theses and Dissertations
  4. Engineering Cancer Vaccines with Ionic Liquids

Engineering Cancer Vaccines with Ionic Liquids

Open/View files
2026.01.05_DR_Dissertation.pdf (39.03 MB)
Date
February 27, 2026
Author(s)
Rodrigues, Danika J.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Rodrigues, Danika J.. 2026. Engineering Cancer Vaccines with Ionic Liquids. Doctoral Dissertation, Harvard University Graduate School of Arts and Sciences.
Abstract
Cancer remains one of the leading causes of death worldwide, and despite advances in detection and treatment, achieving durable immune protection against recurrence remains a major challenge. Immunotherapy harnesses the body’s own immune system to recognize and eliminate cancer cells and has revolutionized cancer treatment. However, many patients fail to respond due to tumor heterogeneity and immune suppression. Cancer vaccines that utilize whole tumor cells offer a promising route to generate antitumor immunity by presenting a broad set of highly matched antigens as they use tumors as the source of antigen. Despite their rich antigen repertoire and high personalization, conventional whole tumor cell cancer vaccines have demonstrated limited clinical success due to insufficient immunogenicity. Traditional approaches, such as genetic engineering or cell surface modification, can enhance immune stimulation but are often labor-intensive, technically complex, and limited in scalability. Therefore, a simple, modular, and effective method to integrate potent immunostimulatory signals directly into whole tumor cell vaccines could substantially enhance efficacy, manufacturability, and scalability. Ionic liquids (ILs) are bulky salts comprised of organic cations and anions with a melting point below 100°C. They are highly tunable and have previously been demonstrated to have abilities in crossing biological barriers. In my dissertation research, I present a facile method to load immunostimulatory CpG oligodeoxynucleotides (ODN) into tumor cells undergoing immunogenic cell death using an ionic liquid-containing cocktail, permitting cell modification in a single step for cancer vaccination. Results indicate that these adjuvant-loaded tumor cells (called IL-Vax) enhance the uptake by dendritic cells (DCs) and their subsequent activation. IL-Vax offers strong protection against tumor growth in a prophylactic setting with 100% survival in vaccinated mice 60 days post-challenge. Furthermore, IL-Vax combined with immune checkpoint blockade leads to slowed tumor growth and a 60% increase in median survival in B16F10 melanoma tumor-bearing mice. Our strategy enables modularity to load different cargos or cargo combinations which may be conducive for additional tailoring of such vaccines and potentially other cell loading applications.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
URI
https://dash.harvard.edu/handle/1/42731121
Subjects

cancer vaccine

cargo loading

ionic liquid

whole tumor cell

Bioengineering

Collection
FAS Theses and Dissertations
Metrics
Repository logo
  • CONTACT US
  • OSRDS
  • ABOUT DASH
  • DEPOSITING TO DASH
  • TERMS OF USE
  • REQUEST A WAIVER
  • TAKE DOWN POLICY
  • NAME CHANGE POLICY
  • HARVARD OA POLICIES
  • DASH SUBMITTER AGREEMENT
  • Accessibility
  • Privacy
Creative Commons License BY
Creative Commons Attribution 4.0 International License

Except where otherwise noted, this work is subject to a Creative Commons Attribution 4.0 International License,
which allows anyone to share and adapt our material as long as proper attribution is given.
For details and exceptions, see the Harvard Library Copyright Policy
©2024 Presidents and Fellows of Harvard College.